EGEI new PR, Chinese patent....see below
eGene Will be Granted Chinese Patent for DNA Analyzer Technology
MONDAY, MARCH 27, 2006 2:26 PM
- BusinessWire
EGEI
1.25 -0.61
Enter Symbol:
Enter Keyword:
IRVINE, Calif., Mar 27, 2006 (BUSINESS WIRE) -- eGene Inc. (EGEI) (the "Company"), developer of a revolutionary high-performance genetic analysis technology, today announced the Company has received confirmation from the China Patent Office of its decision to grant a patent for "OPTICAL DETECTION IN A MULTI-CHANNEL BIO-SEPARATION SYSTEM." This marks the Company's eighth patent worldwide.
Ming S. Liu, acting CEO of eGene, made the announcement noting: "We continue to strengthen our patent portfolio with the addition of this Chinese patent. We believe our portable HDA-GT12(TM) Genetic Analyzer has potential for any number of important uses, among them controlling transmission of infectious diseases through use at locations where DNA can be screened for viral or bacterial signatures; assisting in the development of 'designer drugs' where a patient's DNA is compared to that of a specific drug to determine if that drug will be effective on that individual or if side effects might occur; academic research; and criminal DNA analysis."
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide, including Taiwan's disease control center, and has been developed to use solid-state light sources and micro-optical collectors to make the system compact and affordable. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs RNA and oligonucleotide quality checks, as well as fast DNA sample screening, high-resolution DNA fragment analysis (2-5bp) and large DNA fragments analysis (up to 10Kb). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. (www.egeneinc. com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr. com
or
Andrew Ponzo, 312-943-1100, ext. 17
aponzo@janispr. com
AI
